MovDisordV3, PascalFrancis, Corpus, bibRecord, 002655

Drugs to treat urinary frequency, urgency, and/or urge incontinence

Identifieur interne : 002655 ( PascalFrancis/Corpus ); précédent : 002654; suivant : 002656

Drugs to treat urinary frequency, urgency, and/or urge incontinence

Auteurs :

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0471079

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Vessie neurogène, Incontinence urinaire, Dysurie, Médecine factuelle, Essai clinique, Oxybutynine, Chimiothérapie, Spasmolytique, Imipramine, Amitriptyline, Flavoxate, Prazosine, Traitement, Complication, Article synthèse, Homme, Propivérine, Toltérodine, Composé tricyclique.

English descriptors

KwdEn :
- Amitriptyline, Antispasmodic agent, Chemotherapy, Clinical trial, Complication, Dysuria, Evidence-based medicine, Flavoxate, Human, Imipramine, Neurogenic bladder, Oxybutynin, Parkinson disease, Prazosin, Propiverine, Review, Tolterodine, Treatment, Tricyclic compound, Urinary incontinence.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@3 SUP4`
A08	`01`	`1`	`ENG`	`@1 Drugs to treat urinary frequency, urgency, and/or urge incontinence`
A09	`01`	`1`	`ENG`	`@1 Management of Parkinson's disease: an evidence-based review`
A12	`01`	`1`		`@1 GOETZ (C. G.)`
A12	`02`	`1`		`@1 KOLLER (W. C.)`
A12	`03`	`1`		`@1 POEWE (W.)`
A12	`04`	`1`		`@1 RASCOL (O.)`
A12	`05`	`1`		`@1 SAMPAIO (C.)`
A12	`06`	`1`		`@1 BRIN (M. F.)`
A12	`07`	`1`		`@1 LEES (A. J.)`
A12	`08`	`1`		`@1 LEWITT (P.)`
A12	`09`	`1`		`@1 LOZANO (A.)`
A12	`10`	`1`		`@1 MIZUNO (Y.)`
A12	`11`	`1`		`@1 NUTT (J.)`
A12	`12`	`1`		`@1 OERTEL (W.)`
A12	`13`	`1`		`@1 OLANOW (C. W.)`
A12	`14`	`1`		`@1 TOLOSA (E.)`
A12	`15`	`1`		`@1 BREFEL-COURBON (C.)`
A12	`16`	`1`		`@1 EICHHORN (T.)`
A12	`17`	`1`		`@1 FERREIRA (J.)`
A12	`18`	`1`		`@1 KATZENSCHLAGER (R.)`
A12	`19`	`1`		`@1 LUGINGER (E.)`
A12	`20`	`1`		`@1 PASTOR (P.)`
A12	`21`	`1`		`@1 SEPPI (K.)`
A12	`22`	`1`		`@1 SPIEKER (S.)`
A12	`23`	`1`		`@1 PEARLMAN (S.)`
A18	`01`	`1`		`@1 Movement Disorder Society @2 Milwaukee, WI @3 USA`
A20				`@2 S108-S109`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000108923890160`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 2 p.1/4`
A47	`01`	`1`		`@0 02-0471079`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02I`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Vessie neurogène @5 04`
C03	`02`	`X`	`ENG`	`@0 Neurogenic bladder @5 04`
C03	`02`	`X`	`SPA`	`@0 Vejiga neurógena @5 04`
C03	`03`	`X`	`FRE`	`@0 Incontinence urinaire @5 05`
C03	`03`	`X`	`ENG`	`@0 Urinary incontinence @5 05`
C03	`03`	`X`	`SPA`	`@0 Incontinencia urinaria @5 05`
C03	`04`	`X`	`FRE`	`@0 Dysurie @5 06`
C03	`04`	`X`	`ENG`	`@0 Dysuria @5 06`
C03	`04`	`X`	`SPA`	`@0 Disuria @5 06`
C03	`05`	`X`	`FRE`	`@0 Médecine factuelle @5 07`
C03	`05`	`X`	`ENG`	`@0 Evidence-based medicine @5 07`
C03	`05`	`X`	`SPA`	`@0 Medicina basada en pruebas @5 07`
C03	`06`	`X`	`FRE`	`@0 Essai clinique @5 08`
C03	`06`	`X`	`ENG`	`@0 Clinical trial @5 08`
C03	`06`	`X`	`SPA`	`@0 Ensayo clínico @5 08`
C03	`07`	`X`	`FRE`	`@0 Oxybutynine @2 NK @2 FR @5 10`
C03	`07`	`X`	`ENG`	`@0 Oxybutynin @2 NK @2 FR @5 10`
C03	`07`	`X`	`SPA`	`@0 Oxibutinina @2 NK @2 FR @5 10`
C03	`08`	`X`	`FRE`	`@0 Chimiothérapie @5 11`
C03	`08`	`X`	`ENG`	`@0 Chemotherapy @5 11`
C03	`08`	`X`	`SPA`	`@0 Quimioterapia @5 11`
C03	`09`	`X`	`FRE`	`@0 Spasmolytique @5 12`
C03	`09`	`X`	`ENG`	`@0 Antispasmodic agent @5 12`
C03	`09`	`X`	`SPA`	`@0 Espasmolítico @5 12`
C03	`10`	`X`	`FRE`	`@0 Imipramine @2 NK @2 FR @5 13`
C03	`10`	`X`	`ENG`	`@0 Imipramine @2 NK @2 FR @5 13`
C03	`10`	`X`	`SPA`	`@0 Imipramina @2 NK @2 FR @5 13`
C03	`11`	`X`	`FRE`	`@0 Amitriptyline @2 NK @2 FR @5 14`
C03	`11`	`X`	`ENG`	`@0 Amitriptyline @2 NK @2 FR @5 14`
C03	`11`	`X`	`SPA`	`@0 Amitriptilina @2 NK @2 FR @5 14`
C03	`12`	`X`	`FRE`	`@0 Flavoxate @2 NK @2 FR @5 15`
C03	`12`	`X`	`ENG`	`@0 Flavoxate @2 NK @2 FR @5 15`
C03	`12`	`X`	`SPA`	`@0 Flavoxato @2 NK @2 FR @5 15`
C03	`13`	`X`	`FRE`	`@0 Prazosine @2 NK @2 FR @5 16`
C03	`13`	`X`	`ENG`	`@0 Prazosin @2 NK @2 FR @5 16`
C03	`13`	`X`	`SPA`	`@0 Prazosina @2 NK @2 FR @5 16`
C03	`14`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`14`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`14`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`15`	`X`	`FRE`	`@0 Complication @5 18`
C03	`15`	`X`	`ENG`	`@0 Complication @5 18`
C03	`15`	`X`	`SPA`	`@0 Complicación @5 18`
C03	`16`	`X`	`FRE`	`@0 Article synthèse @5 19`
C03	`16`	`X`	`ENG`	`@0 Review @5 19`
C03	`16`	`X`	`SPA`	`@0 Artículo síntesis @5 19`
C03	`17`	`X`	`FRE`	`@0 Homme @5 20`
C03	`17`	`X`	`ENG`	`@0 Human @5 20`
C03	`17`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`18`	`X`	`FRE`	`@0 Propivérine @2 NK @2 FR @5 23`
C03	`18`	`X`	`ENG`	`@0 Propiverine @2 NK @2 FR @5 23`
C03	`18`	`X`	`SPA`	`@0 Propiverina @2 NK @2 FR @5 23`
C03	`19`	`X`	`FRE`	`@0 Toltérodine @2 NK @2 FR @5 24`
C03	`19`	`X`	`ENG`	`@0 Tolterodine @2 NK @2 FR @5 24`
C03	`19`	`X`	`SPA`	`@0 Tolterodina @2 NK @2 FR @5 24`
C03	`20`	`X`	`FRE`	`@0 Composé tricyclique @5 33`
C03	`20`	`X`	`ENG`	`@0 Tricyclic compound @5 33`
C03	`20`	`X`	`SPA`	`@0 Compuesto tricíclico @5 33`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Appareil urinaire pathologie @5 45`
C07	`06`	`X`	`ENG`	`@0 Urinary system disease @5 45`
C07	`06`	`X`	`SPA`	`@0 Aparato urinario patología @5 45`
C07	`07`	`X`	`FRE`	`@0 Voie urinaire pathologie @5 46`
C07	`07`	`X`	`ENG`	`@0 Urinary tract disease @5 46`
C07	`07`	`X`	`SPA`	`@0 Vía urinaria patología @5 46`
C07	`08`	`X`	`FRE`	`@0 Vessie pathologie @5 47`
C07	`08`	`X`	`ENG`	`@0 Bladder disease @5 47`
C07	`08`	`X`	`SPA`	`@0 Vejiga patología @5 47`
C07	`09`	`X`	`FRE`	`@0 Trouble neurologique @5 48`
C07	`09`	`X`	`ENG`	`@0 Neurological disorder @5 48`
C07	`09`	`X`	`SPA`	`@0 Trastorno neurológico @5 48`
C07	`10`	`X`	`FRE`	`@0 Système nerveux autonome pathologie @5 49`
C07	`10`	`X`	`ENG`	`@0 Diseases of the autonomic nervous system @5 49`
C07	`10`	`X`	`SPA`	`@0 Sistema nervioso autónomo patología @5 49`
C07	`11`	`X`	`FRE`	`@0 Trouble miction @5 50`
C07	`11`	`X`	`ENG`	`@0 Voiding dysfunction @5 50`
C07	`11`	`X`	`SPA`	`@0 Trastorno micción @5 50`
N21				`@1 273`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0471079 INIST
ET :	Drugs to treat urinary frequency, urgency, and/or urge incontinence
AU :	GOETZ (C. G.); KOLLER (W. C.); POEWE (W.); RASCOL (O.); SAMPAIO (C.); BRIN (M. F.); LEES (A. J.); LEWITT (P.); LOZANO (A.); MIZUNO (Y.); NUTT (J.); OERTEL (W.); OLANOW (C. W.); TOLOSA (E.); BREFEL-COURBON (C.); EICHHORN (T.); FERREIRA (J.); KATZENSCHLAGER (R.); LUGINGER (E.); PASTOR (P.); SEPPI (K.); SPIEKER (S.); PEARLMAN (S.)
AF :	Movement Disorder Society/Milwaukee, WI/Etats-Unis
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. SUP4; S108-S109; Bibl. 2 p.1/4
LA :	Anglais
CC :	002B02I
FD :	Parkinson maladie; Vessie neurogène; Incontinence urinaire; Dysurie; Médecine factuelle; Essai clinique; Oxybutynine; Chimiothérapie; Spasmolytique; Imipramine; Amitriptyline; Flavoxate; Prazosine; Traitement; Complication; Article synthèse; Homme; Propivérine; Toltérodine; Composé tricyclique
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Appareil urinaire pathologie; Voie urinaire pathologie; Vessie pathologie; Trouble neurologique; Système nerveux autonome pathologie; Trouble miction
ED :	Parkinson disease; Neurogenic bladder; Urinary incontinence; Dysuria; Evidence-based medicine; Clinical trial; Oxybutynin; Chemotherapy; Antispasmodic agent; Imipramine; Amitriptyline; Flavoxate; Prazosin; Treatment; Complication; Review; Human; Propiverine; Tolterodine; Tricyclic compound
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Urinary system disease; Urinary tract disease; Bladder disease; Neurological disorder; Diseases of the autonomic nervous system; Voiding dysfunction
SD :	Parkinson enfermedad; Vejiga neurógena; Incontinencia urinaria; Disuria; Medicina basada en pruebas; Ensayo clínico; Oxibutinina; Quimioterapia; Espasmolítico; Imipramina; Amitriptilina; Flavoxato; Prazosina; Tratamiento; Complicación; Artículo síntesis; Hombre; Propiverina; Tolterodina; Compuesto tricíclico
LO :	INIST-20953.354000108923890160
ID :	02-0471079

Links to Exploration step

Pascal:02-0471079

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Drugs to treat urinary frequency, urgency, and/or urge incontinence</title>
<author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C. G." last="Goetz">C. G. Goetz</name>
<affiliation><inist:fA14 i1="01" i2="1"><s1>Movement Disorder Society</s1>
<s2>Milwaukee, WI</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
</author>
<author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
</author>
<author><name sortKey="Sampaio, C" sort="Sampaio, C" uniqKey="Sampaio C" first="C." last="Sampaio">C. Sampaio</name>
</author>
<author><name sortKey="Brin, M F" sort="Brin, M F" uniqKey="Brin M" first="M. F." last="Brin">M. F. Brin</name>
</author>
<author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">A. J. Lees</name>
</author>
<author><name sortKey="Lewitt, P" sort="Lewitt, P" uniqKey="Lewitt P" first="P." last="Lewitt">P. Lewitt</name>
</author>
<author><name sortKey="Lozano, A" sort="Lozano, A" uniqKey="Lozano A" first="A." last="Lozano">A. Lozano</name>
</author>
<author><name sortKey="Mizuno, Y" sort="Mizuno, Y" uniqKey="Mizuno Y" first="Y." last="Mizuno">Y. Mizuno</name>
</author>
<author><name sortKey="Nutt, J" sort="Nutt, J" uniqKey="Nutt J" first="J." last="Nutt">J. Nutt</name>
</author>
<author><name sortKey="Oertel, W" sort="Oertel, W" uniqKey="Oertel W" first="W." last="Oertel">W. Oertel</name>
</author>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
</author>
<author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name>
</author>
<author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
</author>
<author><name sortKey="Eichhorn, T" sort="Eichhorn, T" uniqKey="Eichhorn T" first="T." last="Eichhorn">T. Eichhorn</name>
</author>
<author><name sortKey="Ferreira, J" sort="Ferreira, J" uniqKey="Ferreira J" first="J." last="Ferreira">J. Ferreira</name>
</author>
<author><name sortKey="Katzenschlager, R" sort="Katzenschlager, R" uniqKey="Katzenschlager R" first="R." last="Katzenschlager">R. Katzenschlager</name>
</author>
<author><name sortKey="Luginger, E" sort="Luginger, E" uniqKey="Luginger E" first="E." last="Luginger">E. Luginger</name>
</author>
<author><name sortKey="Pastor, P" sort="Pastor, P" uniqKey="Pastor P" first="P." last="Pastor">P. Pastor</name>
</author>
<author><name sortKey="Seppi, K" sort="Seppi, K" uniqKey="Seppi K" first="K." last="Seppi">K. Seppi</name>
</author>
<author><name sortKey="Spieker, S" sort="Spieker, S" uniqKey="Spieker S" first="S." last="Spieker">S. Spieker</name>
</author>
<author><name sortKey="Pearlman, S" sort="Pearlman, S" uniqKey="Pearlman S" first="S." last="Pearlman">S. Pearlman</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0471079</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0471079 INIST</idno>
<idno type="RBID">Pascal:02-0471079</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002655</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Drugs to treat urinary frequency, urgency, and/or urge incontinence</title>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amitriptyline</term>
<term>Antispasmodic agent</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Complication</term>
<term>Dysuria</term>
<term>Evidence-based medicine</term>
<term>Flavoxate</term>
<term>Human</term>
<term>Imipramine</term>
<term>Neurogenic bladder</term>
<term>Oxybutynin</term>
<term>Parkinson disease</term>
<term>Prazosin</term>
<term>Propiverine</term>
<term>Review</term>
<term>Tolterodine</term>
<term>Treatment</term>
<term>Tricyclic compound</term>
<term>Urinary incontinence</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Vessie neurogène</term>
<term>Incontinence urinaire</term>
<term>Dysurie</term>
<term>Médecine factuelle</term>
<term>Essai clinique</term>
<term>Oxybutynine</term>
<term>Chimiothérapie</term>
<term>Spasmolytique</term>
<term>Imipramine</term>
<term>Amitriptyline</term>
<term>Flavoxate</term>
<term>Prazosine</term>
<term>Traitement</term>
<term>Complication</term>
<term>Article synthèse</term>
<term>Homme</term>
<term>Propivérine</term>
<term>Toltérodine</term>
<term>Composé tricyclique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s3>SUP4</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Drugs to treat urinary frequency, urgency, and/or urge incontinence</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Management of Parkinson's disease: an evidence-based review</s1>
</fA09>
<fA12 i1="01" i2="1"><s1>GOETZ (C. G.)</s1>
</fA12>
<fA12 i1="02" i2="1"><s1>KOLLER (W. C.)</s1>
</fA12>
<fA12 i1="03" i2="1"><s1>POEWE (W.)</s1>
</fA12>
<fA12 i1="04" i2="1"><s1>RASCOL (O.)</s1>
</fA12>
<fA12 i1="05" i2="1"><s1>SAMPAIO (C.)</s1>
</fA12>
<fA12 i1="06" i2="1"><s1>BRIN (M. F.)</s1>
</fA12>
<fA12 i1="07" i2="1"><s1>LEES (A. J.)</s1>
</fA12>
<fA12 i1="08" i2="1"><s1>LEWITT (P.)</s1>
</fA12>
<fA12 i1="09" i2="1"><s1>LOZANO (A.)</s1>
</fA12>
<fA12 i1="10" i2="1"><s1>MIZUNO (Y.)</s1>
</fA12>
<fA12 i1="11" i2="1"><s1>NUTT (J.)</s1>
</fA12>
<fA12 i1="12" i2="1"><s1>OERTEL (W.)</s1>
</fA12>
<fA12 i1="13" i2="1"><s1>OLANOW (C. W.)</s1>
</fA12>
<fA12 i1="14" i2="1"><s1>TOLOSA (E.)</s1>
</fA12>
<fA12 i1="15" i2="1"><s1>BREFEL-COURBON (C.)</s1>
</fA12>
<fA12 i1="16" i2="1"><s1>EICHHORN (T.)</s1>
</fA12>
<fA12 i1="17" i2="1"><s1>FERREIRA (J.)</s1>
</fA12>
<fA12 i1="18" i2="1"><s1>KATZENSCHLAGER (R.)</s1>
</fA12>
<fA12 i1="19" i2="1"><s1>LUGINGER (E.)</s1>
</fA12>
<fA12 i1="20" i2="1"><s1>PASTOR (P.)</s1>
</fA12>
<fA12 i1="21" i2="1"><s1>SEPPI (K.)</s1>
</fA12>
<fA12 i1="22" i2="1"><s1>SPIEKER (S.)</s1>
</fA12>
<fA12 i1="23" i2="1"><s1>PEARLMAN (S.)</s1>
</fA12>
<fA18 i1="01" i2="1"><s1>Movement Disorder Society</s1>
<s2>Milwaukee, WI</s2>
<s3>USA</s3>
</fA18>
<fA20><s2>S108-S109</s2>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000108923890160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>2 p.1/4</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0471079</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02I</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Vessie neurogène</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Neurogenic bladder</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vejiga neurógena</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Incontinence urinaire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Urinary incontinence</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Incontinencia urinaria</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Dysurie</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dysuria</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Disuria</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Médecine factuelle</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Evidence-based medicine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Medicina basada en pruebas</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Oxybutynine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Oxybutynin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Oxibutinina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Spasmolytique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Antispasmodic agent</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Espasmolítico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Imipramine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Imipramine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Imipramina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Amitriptyline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Amitriptyline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Amitriptilina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Flavoxate</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Flavoxate</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Flavoxato</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>15</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Prazosine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Prazosin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Prazosina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>16</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Complication</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Complication</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Complicación</s0>
<s5>18</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Review</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>19</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Propivérine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Propiverine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Propiverina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>23</s5>
</fC03>
<fC03 i1="19" i2="X" l="FRE"><s0>Toltérodine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>24</s5>
</fC03>
<fC03 i1="19" i2="X" l="ENG"><s0>Tolterodine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>24</s5>
</fC03>
<fC03 i1="19" i2="X" l="SPA"><s0>Tolterodina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>24</s5>
</fC03>
<fC03 i1="20" i2="X" l="FRE"><s0>Composé tricyclique</s0>
<s5>33</s5>
</fC03>
<fC03 i1="20" i2="X" l="ENG"><s0>Tricyclic compound</s0>
<s5>33</s5>
</fC03>
<fC03 i1="20" i2="X" l="SPA"><s0>Compuesto tricíclico</s0>
<s5>33</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Appareil urinaire pathologie</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Urinary system disease</s0>
<s5>45</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Aparato urinario patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Voie urinaire pathologie</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Urinary tract disease</s0>
<s5>46</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Vía urinaria patología</s0>
<s5>46</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Vessie pathologie</s0>
<s5>47</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Bladder disease</s0>
<s5>47</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Vejiga patología</s0>
<s5>47</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>48</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>48</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>48</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Système nerveux autonome pathologie</s0>
<s5>49</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Diseases of the autonomic nervous system</s0>
<s5>49</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Sistema nervioso autónomo patología</s0>
<s5>49</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Trouble miction</s0>
<s5>50</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Voiding dysfunction</s0>
<s5>50</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Trastorno micción</s0>
<s5>50</s5>
</fC07>
<fN21><s1>273</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0471079 INIST</NO>
<ET>Drugs to treat urinary frequency, urgency, and/or urge incontinence</ET>
<AU>GOETZ (C. G.); KOLLER (W. C.); POEWE (W.); RASCOL (O.); SAMPAIO (C.); BRIN (M. F.); LEES (A. J.); LEWITT (P.); LOZANO (A.); MIZUNO (Y.); NUTT (J.); OERTEL (W.); OLANOW (C. W.); TOLOSA (E.); BREFEL-COURBON (C.); EICHHORN (T.); FERREIRA (J.); KATZENSCHLAGER (R.); LUGINGER (E.); PASTOR (P.); SEPPI (K.); SPIEKER (S.); PEARLMAN (S.)</AU>
<AF>Movement Disorder Society/Milwaukee, WI/Etats-Unis</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. SUP4; S108-S109; Bibl. 2 p.1/4</SO>
<LA>Anglais</LA>
<CC>002B02I</CC>
<FD>Parkinson maladie; Vessie neurogène; Incontinence urinaire; Dysurie; Médecine factuelle; Essai clinique; Oxybutynine; Chimiothérapie; Spasmolytique; Imipramine; Amitriptyline; Flavoxate; Prazosine; Traitement; Complication; Article synthèse; Homme; Propivérine; Toltérodine; Composé tricyclique</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Appareil urinaire pathologie; Voie urinaire pathologie; Vessie pathologie; Trouble neurologique; Système nerveux autonome pathologie; Trouble miction</FG>
<ED>Parkinson disease; Neurogenic bladder; Urinary incontinence; Dysuria; Evidence-based medicine; Clinical trial; Oxybutynin; Chemotherapy; Antispasmodic agent; Imipramine; Amitriptyline; Flavoxate; Prazosin; Treatment; Complication; Review; Human; Propiverine; Tolterodine; Tricyclic compound</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Urinary system disease; Urinary tract disease; Bladder disease; Neurological disorder; Diseases of the autonomic nervous system; Voiding dysfunction</EG>
<SD>Parkinson enfermedad; Vejiga neurógena; Incontinencia urinaria; Disuria; Medicina basada en pruebas; Ensayo clínico; Oxibutinina; Quimioterapia; Espasmolítico; Imipramina; Amitriptilina; Flavoxato; Prazosina; Tratamiento; Complicación; Artículo síntesis; Hombre; Propiverina; Tolterodina; Compuesto tricíclico</SD>
<LO>INIST-20953.354000108923890160</LO>
<ID>02-0471079</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002655 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002655 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0471079
   |texte=   Drugs to treat urinary frequency, urgency, and/or urge incontinence
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Drugs to treat urinary frequency, urgency, and/or urge incontinence

Drugs to treat urinary frequency, urgency, and/or urge incontinence

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri